签约仪式上，澳斯康生物集团董事长兼总裁罗顺对与科兴制药的合作充满期待，他表示，科兴制药近几 年在国际化道路上进展迅速，澳斯康生物将发挥自身优势，以全球视野和前沿技术，加快双方合作项目 的研发进程。 科兴制药董事长邓学勤也表示，澳斯康生物团队在单抗、多抗、ADC等大分子领域拥有CMC（化学、 制造和控制）开发与商业化生产及申报的丰富经验，未来双方将紧密合作，研发符合中、美、欧监管标 准的高品质生物类似药，丰富公司欧美产品线，抢占市场先机。 科兴制药启动针对欧美市场的生物类似药合作开发项目，正是基于对生物类似药临床价值支撑商业端持 续高增长的坚定判断。依托公司在国际市场的前瞻性拓展、欧美市场的精准布局及新兴市场的深度耕 耘，科兴制药有望实现"弯道超车"，为未来全球化竞争与突破奠定坚实基础。 中证报中证网讯（王珞）近日，科兴制药（688136.SH）宣布与上海澳斯康生物制药有限公司（澳斯康 生物全资子公司）达成战略合作关系，合作研发KXBS001生物类似药，双方在深圳举办签约仪式。这 一合作标志着科兴制药向欧美生物类似药市场进发。 IQVIA（艾昆纬）研究报告显示，欧盟目前仍是全球生物类似药的主流市场，其市场价值占 ...

Core Viewpoint - Recently, Kexing Pharmaceutical and Auscan Biopharmaceutical Co., Ltd. have established a strategic partnership to jointly develop the KXBS001 biosimilar, marking their entry into the European and American biosimilar markets [1] Group 1: Strategic Partnership - Kexing Pharmaceutical has formed a strategic collaboration with Auscan Biopharmaceutical to develop biosimilars [1] - The partnership aims to leverage both companies' strengths to accelerate the research and development process of the KXBS001 biosimilar [1] Group 2: Market Opportunities - The European Medicines Agency (EMA) has recently announced a draft plan to simplify the review process for biosimilars, potentially providing a "fast track" for domestic pharmaceutical companies to enter the EU market [1] - According to an IQVIA report, the EU accounts for approximately 40% of the global biosimilar market value [1] Group 3: Company Strategies - Kexing Pharmaceutical adheres to an "innovation + internationalization" strategy and has developed a comprehensive antibody technology platform with capabilities across various therapeutic areas, including antiviral, oncology, and autoimmune diseases [1] - Auscan Biopharmaceutical's chairman highlighted Kexing's rapid progress in internationalization and expressed confidence in leveraging cutting-edge technology to enhance the collaboration [1] - Kexing's chairman noted that Auscan's team possesses extensive experience in CMC development and commercialization in the large molecule field, indicating a strong foundation for future collaboration [1]